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Abstract. The already established and widely used intravenous application of recombinant tissue plasminogen activator
as a re-opening strategy for acute vessel occlusion in ischemic stroke was recently added by mechanical thrombectomy,
representing a fundamental progress in evidence-based medicine to improve the patient’s outcome. This has been paralleled
by a swift increase in our understanding of pathomechanisms underlying many neurovascular diseases and most prevalent
forms of dementia. Taken together, these current advances offer the potential to overcome almost two decades of marginally
successful translational research on stroke and dementia, thereby spurring the entire field of translational neuroscience.
Moreover, they may also pave the way for the renaissance of classical neuroprotective paradigms.
This review reports and summarizes some of the most interesting and promising recent achievements in neurovascular and
dementia research. It highlights sessions from the 9th International Symposium on Neuroprotection and Neurorepair that
have been discussed from April 19th to 22nd in Leipzig, Germany. To acknowledge the emerging culture of interdisciplinary
collaboration and research, special emphasis is given on translational stories ranging from fundamental research on neurode-
and -regeneration to late stage translational or early stage clinical investigations.
Keywords: Alzheimer’s disease, brain, cerebral ischemia, cerebral small vessel disease, dementia, experimental therapy,
hemorrhage, in vivo imaging, neuroimmunology, neuroprotection, neurorepair, sex differences, stroke, translational research,
vascular cognitive impairment
1. Introduction
Neurovascular research is at a turning point. The
successful attempt to widen the therapeutic time
window for ischemic stroke (Hacke et al., 2008) has
recently been added by a handful of randomized
controlled clinical trials demonstrating efficacy of
novel intravascular recanalization procedures (i.e.
mechanical thrombectomy; Campbell et al., 2015) in
patients with large vessel occlusion, a situation that
is usually associated with malignant edema forma-
tion and high mortality. After numerous translational
failures of neuroprotective attempts during the last
decades (e.g. NXY-059 in the SAINT trials; Diener
et al., 2008), this situation might pave the way for a
novel concept of combined endovascular and neu-
roprotective therapies (Henninger & Fisher, 2016;
Lo & Ning, 2016). At the same time, progress in
the treatment of Alzheimer’s disease (AD) and other
forms of dementia seems to accelerate (Venigalla
et al., 2016; Deak et al., 2016). We also gain more
and more detailed insight on the role of gene and
protein expression in Alzheimer’s disease. For exam-
ple, the presence of pyroglutamylated A deposits
correlates well with mental status and disease pro-
gression (Mandler et al., 2014). This knowledge
might ultimately lead to novel therapeutic target can-
didates. In vascular dementia, the role of central and
peripheral inflammatory responses is increasingly
recognized, exhibiting interesting similarities to what
has been described in acute neurovascular insults
such as stroke (Kaiser et al., 2014). Based on our
augmented understanding of underlying pathophysi-
ological mechanisms, the advent of novel therapeutic
options for neurovascular diseases and highly preva-
lent forms of cognitive impairment becomes more
likely.
The biannual International Symposium on Neu-
roprotection and Neurorepair (ISN&N) meeting
series aims to bring together leading experts and
internationally recognized pioneers in the field to
discuss recent advances in fundamental research,
translational programs, and clinical implementation.
Continuing the tradition of previous meetings (Boltze
et al., 2011, 2012), the 9th ISN&N was jointly
organized by the University of Leipzig, Fraunhofer-
Institute for Cell Therapy and Immunology, Leipzig
and the Fraunhofer Research Institution of Marine
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Biotechnology, Lu¨beck. It took place in Leipzig,
Germany from April 19th to 22nd, 2016 and became
the largest in the series’ history by attracting more
than 430 participants from all over the world. This
resulted in an atmosphere of intensive scientific
exchange and discussions. In this review, we will
highlight some of the most exciting findings that have
been reported at the 9th ISN&N. Particular focus
is given on translational developments. To achieve
this, we preferably selected contributions and ses-
sions providing comprehensive set of data reaching
form fundamental discoveries to clinical or at least
late stage preclinical results. Special emphasis was
given on investigational endpoints being of direct rel-
evance for the clinical situation. Since we might only
fail in an attempt to refer to each outstanding talk
or fruitful discussion, this review instead provides
a cross-selection of excellent contributions from all
research disciplines covered by the meeting.
2. Molecules and mechanisms: News from
fundamental research
2.1. Noncoding RNAs and neuroprotection
In mammals, the protein-coding ribonucleic acids
(RNAs) constitute <2% of the transcriptional out-
put, while noncoding RNAs (ncRNAs) of different
classes comprise the remaining 98%. Recent studies
showed that experimental stroke alters the expres-
sion profiles of various classes of ncRNAs including
microRNAs (miRNAs) and long noncoding RNAs
(lncRNAs). Hence, the therapeutic potential of ncR-
NAs in promoting neuroprotection after stroke has
been discussed at the meeting.
Rona Giffard (Palo Alto, USA) showed that
miRNAs can be manipulated to influence post-
stroke outcome. She demonstrated that reducing
the levels of miR-181 with either pretreatment or
post-treatment with an antagomiR-181 effectively
decreased the infarction in mouse models of stroke.
Particularly, post-treatment leads to long lasting
behavioral improvement (Xu et al., 2015). The miR-
181 antagomiR was observed to target molecules that
promote apoptosis, oxidative stress and inflamma-
tion. Dr. Giffard further showed that manipulation
of miR-210 improves mitochondrial function which
promotes survival of newborn neurons as well as
reduces inflammation. This dual targeting shows
promise to improve post stroke recovery (Ouyang
et al., 2015).
Raghu Vemuganti (Madison, USA) showed that,
miR-29 and miR-7 are major miRNA families
that are considered as pro-survival microRNAs and
play essential roles in the healthy brain. Following
focal ischemia, miR-29c and miR-7a are downreg-
ulated significantly and when these miRNAs were
replenished using specific premiRs and/or miRNA
mimics, post-ischemic brain damage was curtailed
with improved functional recovery indicating their
essential neuroprotective role (Pandi et al., 2013;
Kim et al., 2016). It was further shown that a
lncRNA called FosDT induced after stroke mediates
ischemic brain damage and treatment with a siRNA
cocktail that targets FosDT significantly protected
the brain following focal ischemia. Mechanistically,
FosDT siRNA-mediated neuroprotection was asso-
ciated with curtailed scaffolding of the chromatin
modifying proteins Sin3A and coREST to the tran-
scription factor REST that is known to promote
neuronal death after stroke (Mehta et al., 2015).
Farida Sohrabji (College Station, USA) showed
that outcome following manipulation of miRNAs
after stroke depends on both age and sex. A case
in point is the miRNA Let7f, which negatively
regulates the neuroprotective growth factor insulin
growth factor (IGF)-1. In a study using adult and
middle aged male and female rats, an antagomir to
Let7f (anti-Let7f) was delivered intracerebroventric-
ularly 4 hours post stroke (Selvamani et al., 2012).
In adult female rats, anti-Let7f significantly reduced
infarct volume and improved sensory motor per-
formance. However, this antagomir had no effect
on stroke outcomes in males or ovariectomized
females. Furthermore, in middle-aged, acyclic
females, anti-Let7f, paradoxically, increased infarct
volume. These data emphasize the complex interac-
tion between the constitutive endocrine milieu and
miRNA mediators, and underscore the importance
of considering both sexes in developing stroke
interventions.
Kejie Yin (Ann Arbor, USA) reported that the
miR-15a/16-1 cluster is involved in the regulation of
post-ischemic angiogenesis. Levels of miR-15a/16-
1 are increased in the cerebrovasculature in mice
at 7 days post stroke. Transgenic overexpression of
miR-15a/16-1 leads to reduced cerebral blood vessel
formation, increased brain infarction and neurolog-
ical deficits in stroke mice (Yin et al., 2012). A
series of in vitro experiments suggested that the miR-
15a/16-1 cluster is a critical mediator in cerebral
angiogenesis after ischemic stroke. Pharmacological
inhibition may be helpful in developing miR-based
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neurorestorative drugs to promote post-stroke func-
tional recovery.
2.2. Proteases before, during and after stroke
The plasminogen activation system was initially
thought to be solely involved in the control of
fibrin degradation by catalyzing the conversion
of plasminogen into plasmin via two serine pro-
teases: tissue-type plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA). How-
ever, it has been recently discovered by Manuel Yepes
(Atlanta, USA) and colleagues that the control of fib-
rinolysis is not the only role of tPA and uPA, and
that instead both PAs are also found in the synapse
where they play a central role in the development of
synaptic plasticity via mechanisms that not always
require their ability to generate plasmin (Wu et al.,
2014, 2015). The group used 8–12 weeks old male
wild-type (Wt) C57BL/6J mice for their studies.
Dendritic spines (DSs) are specialized dendritic
protrusions that receive most of the excitatory input
in the brain; and that are replaced by focal areas of
swelling known as varicosities following the onset
of global cerebral ischemia in adult 2–5 month old
mice (Murphy et al., 2008). Data show that during
the recovery phase from an ischemic stroke, neurons
located in the peri-infarct cortex release uPA, and
the interaction of this uPA with its receptor (uPAR)
promotes the reorganization of the actin cytoskeleton
and the subsequent re-emergence of dendritic spines
from dendritic varicosities. This effect, mediated by
uPA-uPAR, induced profilin expression and cofilin
phosphorylation, leads to the formation of new synap-
tic contacts and recovery of neurological function
after an ischemic injury. Accordingly, treatment with
recombinant uPA (ruPA) promotes dendritic spine
recovery and improvement in neurological function
after ischemic stroke.
Denis Vivien (Caen, France) provided more
insights into the multiple physiological and patho-
physiological roles of tPA. The enzyme can act
on virtually all cell types of the brain, including
neurons, endothelial and glial cells. These actions
are conducted by enzymatic or growth-factor-like
effects on various molecular substrates or recep-
tors. In addition of its fibrinolytic activity, tPA can
also influence NMDA receptors signaling and subse-
quent neuronal fate. Interestingly, the single chain
form of tPA (sc-tPA) is the only one capable to
promote NMDA receptors-mediated neuronal death.
Accordingly, strategies to prevent the tPA-dependent
modulation of NMDA receptor signaling lead to an
increased therapeutic window for tPA treatment in
experimental stroke (Chevilley et al., 2015).
Josune Orbe (Pamplona, Spain) focused on matrix
metalloproteinase (MMP)-10. His group investigated
the therapeutic and protective effect of combining
tPA/MMP-10 as clot-dissolving and neuroprotective
agents after experimental model of ischemic stroke in
C57BL/6J male mice (4 months old), as well as the
molecular pathways involved. tPA/MMP-10 signifi-
cantly reduced the infarct size in the ischemic stroke
model compared with tPA alone. In vitro, MMP-10
reduced tPA-promoted endothelial ionic permeabil-
ity, preserved claudin-5 expression and decreased
ERK1/2 activation. MMP-10 also prevented tPA-
mediated neuronal excitotoxicity and Ca2+ influx.
These findings indicate that MMP-10 improves
tPA-thrombolytic therapy by providing additional
cytoprotection. All reported results were obtained
from experimental models in rodents. Further inves-
tigations are needed to confirm the relevance of these
data in clinical situations.
2.3. Post-translational modiﬁcations
and regulation of gene expression
in neurodegenerative disorders
It is well-known that neurodegenerative disor-
ders, among those the most prominent, Alzheimer’s
disease, are characterized by deposition of post-
translationally modified amyloid peptides (Kummer
& Heneka, 2014). Recent studies suggest that
appearance of modified A correlates with dis-
ease progression and cognitive status of patients
(Morawski et al., 2014; Mandler et al., 2014). Like-
wise, clinical programs have been initiated to target
those forms with novel therapeutics. Moreover, other
factors such as activation of endogenous retroviruses
might contribute to neurodegeneration (Emmer et al.,
2014).
Stephan von Ho¨rsten (Erlangen, Germany)
reported about the putative role of N-terminal modi-
fications of mutant Huntingtin (HTT). HD pathology
was analyzed in HTT transgenic rats of different
age. He pointed out that multiple processes such
as limited proteolysis and pyroglutamate formation
might act together to generate toxic HTT aggregates
in Huntington’s Disease. Victoria Gro¨ger (Halle,
Germany) reviewed the potential role of human
endogenous retroviruses for neurodegenerative
disorders. Activation of envelope protein expression
elicits a strong immune response and subsequent
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neuronal damage. Jochen Walter reported about
phosphorylation of A peptides in Alzheimers’s
disease AD and its influence on the aggregation
behavior of the amyloid peptide (Rezaei-Ghaleh
et al., 2016). Steffen Rossner (Leipzig, Germany)
demonstrated the important role of the chemokine
CCL2 in Alzheimer’s Disease (AD) and the function
of a glutaminyl cyclase (isoQC) for activation of the
chemokine. Pathology was studied in Tg2576 mice,
a mouse model of Alzheimer’s disease. Finally,
Stephan Schilling (Halle, Germany) reported about
endoproteolytic events leading to formation of A3-
42, which is converted into N-terminally modified
pGlu-modified peptides in Alzheimer’s disease.
Summarizing, the reports highlighted that modifi-
cations of proteins represent attractive anchor points
for future drug development.
3. Where translation begins: Novel
pathophysiological insights
3.1. Pressure, penumbra and promising acute
stroke therapies
This symposium focused on strong hypothesis
driven science and research collaborations with par-
ticular potential to translate research from bench
to bedside. David Howells (Hobart, Australia) pre-
sented data regarding the work of his group using
stem cell-derived human neurons as a tool for
assessing candidate drugs and therapies (Howells &
Macleod, 2013). As a prerequisite for translational
attempts, these cells were reproducibly maintained in
culture for weeks. Subsequent testing of various puta-
tive neuroprotectants in different models of in vitro
ischemia produced results largely consistent with in
vivo experimental or clinical trial experience, includ-
ing lack of benefit for NXY-059, and a 4-6 hour
window for benefit of hypothermic neuroprotection
(Antonic et al., 2014).
Damian McLeod (Callaghan, Australia and
Leipzig, Germany) presented in vivodata demonstrat-
ing a previously unknown and edema-independent
mechanism of intracranial pressure (ICP) elevation
24 hours following stroke. Significant ICP eleva-
tion was found even after minor stroke with minimal
subsequent edema. Interestingly, this increase was
prevented by mild hypothermia in adult male Wis-
tar and Sprague–Dawley rats (Murtha et al., 2014;
Murtha et al., 2015). His data demonstrate that ICP
elevation after stroke is a potential cause of the
so called collateral failure in stroke-in-progression
(Fig. 1). Neil Spratt explored potential mechanisms of
this intracranial pressure rise based on data obtained
from adult rats. Presence of ischemic penumbra in
the early phases post stroke was associated with 24
hour ICP elevation, and there appears to be a trigger-
ing substance in the cerebrospinal fluid (Beard et al.,
2016a, 2016b).
Rene´e Turner (Adelaide, Australia) presented data
exploring the role of the neuropeptide substance P
in development of cerebral edema and elevated ICP
following large middle cerebral artery (MCA) stroke
Fig. 1. Increase of infarct core volume due to ICP-caused collateral supply decline. (A) Collateral perfusion helps to limit the extent of the
ischemic core after stroke if ICP remains low to moderate. (B) Steeply increasing ICP can dramatically reduce collateral blood flow after
ischemic stroke, since the cerebral perfusion pressure equals to the mean arterial pressure minus ICP as suggested by the Monro–Kellie
doctrine. Challenging conventional knowledge suggesting that edema is the major cause of ICP increase, Murtha and colleagues could show
that even minor ischemic lesions causing mild edema might lead to significant ICP rises. This may represent an important pathophysiological
mechanism contributing to significant cerebral damage even after initial minor strokes with larger penumbras with good collateralization. A
potential therapeutic strategy might be the application of mild hypothermia, which has been demonstrated to prevent the ICP rise after even
minor strokes. Angiograms were taken from Shuaib et al., 2011.
92 H.-U. Demuth et al. / Proceedings from the 9th International Symposium on Neuroprotection & Neurorepair
in adult sheep. A neurokinin 1 antagonist prevented
ICP elevation in this model, without the marked mid-
line shift seen in untreated animals or some of those
treated with decompressive craniectomy (Gabrielian
et al., 2013). This may represent an alternative, less
invasive approach to treating the edema associated
with large MCA stroke (Corrigan et al., 2016).
Mhairi Macrae (Glasgow, United Kingdom)
presented data regarding a promising theranos-
tic based on Glasgow-Oxygen-Level-Dependent
(GOLD) technology, which provides MRI-based
diagnostic techniques for detection of penumbral tis-
sue alongside improved oxygen delivery to maintain
penumbra viability until blood supply is restored. Ini-
tial studies using rodent stroke models indicated both
diagnostic and treatment potential, and subsequent
studies have included testing in healthy volunteers
and stroke patients, suggesting potential of these
agents to maintain metabolism and prevent lactate
elevation in the penumbra as observed in rats (Murtha
et al., 2015; Robertson et al., 2015).
3.2. Pathophysiology of vascular cognitive
impairment
Chronic cerebrovascular pathology is a leading
cause of dementia, and arguably represents the most
important modifiable risk factor for Alzheimer’s dis-
ease (AD) (Iadecola, 2013). Despite this importance,
the mechanisms and pathways contributing to vascu-
lar cognitive impairment (VCI) have largely remained
elusive.
Gabor Petzold (Bonn, Germany) discussed the
role of pro-inflammatory signaling cascades of the
neurovascular unit in VCI. He provided evidence
that an astrocyte-specific transgenic reduction of
white matter inflammation in a mouse model of
VCI can ameliorate axonal degeneration, demyelina-
tion and gliosis as well as cognitive decline. These
data suggest that, similar to AD (Delekate et al.,
2014), astrocytes might be centrally involved in the
pathophysiology of VCI, and that anti-inflammatory
interventions may prove therapeutically beneficial.
Data were obtained in adult mice (10–14 weeks of
age).
Linked to this work, Karen Horsburgh (Edinburgh,
United Kingdom) discussed the contribution of
microglial proliferation to axon-glial disruption and
impairment of white matter function in a model of
VCI. The VCI model is induced in male C57Bl/6J
wild-type mice (approx. 4 months old) by perma-
nent bilateral carotid artery stenosis resulting in
chronic cerebral hypoperfusion, axon-glial damage
and progressive impairment of white matter function
over three months. She demonstrated that targeting
neuroinflammation dampens microglial proliferation
and improves white matter function in 4 month old
wild-type mice. In TgAPP (J9) mice (4 months
old before the onset of amyloid deposition) after
one-month reduced cerebral perfusion, the levels of
pro-inflammatory proteins are markedly elevated.
Further in another TgAPP model (TgSWDI mice
aged 4 months) reduced perfusion over three months
culminates in accumulation of vascular amyloid and
degenerative changes. This work provides evidence
that reduced cerebral hypoperfusion is a common
mechanism underlying the pathophysiology of VCI
and AD and that neuroinflammation may be a key
target for intervention.
Costantino Iadecola (New York, USA) discussed
the role of vascular factors in conditions associated
with cognitive impairment and dementia. Hyperten-
sion, a major cause of VCI, blocks neurovascular
coupling and impairs endothelial and blood-brain
barrier function through reactive oxygen species
(ROS) generated by NADPH oxidase 2 (Nox2). In
models of AD, there are major cerebrovascular alter-
ations that precede amyloid deposition in the brain
parenchyma (plaques) and blood vessels (amyloid
angiopathy). The mechanisms involve binding of A
to the scavenger receptor CD36, activation of Nox2
and vascular oxidative stress as shown in a study
using 3- to 4-mo-old male C57BL6/J or CD360/0,
and Tg2576 mice (Park et al., 2011). Thus, dele-
tion of CD36 rescues the cerebrovascular dysfunction
in Tg2576 mice (aged 3, 18, and 22 months) and,
remarkably, alleviates cerebral amyloid angiopathy
without affecting amyloid plaques in the parenchyma
(Park et al., 2013). Next, the lab investigated the
mechanisms by which the ROS alter cerebrovascu-
lar function. It was found that A induces DNA
damage and activation of the DNA repair enzyme
polyADP ribose polymerase (PARP) in cerebral
endothelial cells, leading to formation of polyADP
ribose, activation of the ion channel TRPM2 by
ADP ribose, massive increases in endothelial Ca2+,
and endothelial dysfunction (Park et al., 2014). The
latter study was performed in male 3- to 4-month-
old C57BL/6J mice, and mice lacking PARP-1 or
Nox2, as well as in Tg2576 and TRPM2-null mice.
Collectively, these observations indicate that vascu-
lar alterations are important both in vascular and
neurodegenerative dementias and suggest that
targeting vascular risk factors and improving
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cerebrovascular function offers the opportunity to
mitigate their devastating impact on human health.
Tim Murphy (Vancouver, Canada) described an
adult (2–4 months old) mouse model of small-
vessel disease that is characterized by occlusions
resulting from endovascular injection of fluorescent
microspheres that target ∼12m diameter penetrat-
ing arterioles, which can be localized by histology
(Silasi et al., 2015) or in vivo imaging. Advan-
tages of the model are its simplicity with respect to
surgery and ability to recover animals for long-term
studies. Using Thy1-green fluorescent protein (GFP)
transgenic mice, the impact of micro-occlusions on
neuronal structure was determined. Micro-occlusions
in the hippocampus led to microinfarcts in ∼7%
of lodged microspheres cases, while axons within
white matter tracts as well as the striatum and tha-
lamus became bleb-like or disrupted. Neocortical
layer 5 neurons were relatively resistant to struc-
tural damage, with <2% of the lodged microspheres
producing obvious neuronal damage by assessment
of GFP-labeled dendrites. This small vessel disease
model will be used for assessment of regional func-
tional connectivity to understand how small sporadic
lesions affect network dynamics. The model can be
combined with new mouse home-cage imaging sys-
tems where image capture can be automated.
Tracy Farr (Nottingham, United Kingdom) has
been using diffusion tensor imaging to explore
structural changes in connectivity in the adult hypop-
erfused C57BL/6J mouse brain. Graph theory is a
mathematical modeling technique that can advance
our understanding of how the diseased brain changes
by quantifying diffusion trajectories and convert-
ing them into a series of numbers. Hypoperfusion
reduced the number of distinct groups of highly
interconnected brain structures, though connectivity
increased within these sub-groups. Some network
parameters were excellent neuroimaging biomark-
ers, as they were accurate predictors of cognitive
outcome.
3.3. The role of blood in brain injury
While the majority of strokes are of ischemic
nature, mortality is comparably higher following
hemorrhagic stroke, i.e. up to 50% within the first 30
days after the insult (van Asch et al., 2010). Bleeding
can be caused by traumatic brain injury (TBI) or occur
spontaneously in hemorrhagic strokes, while intrac-
erebral (ICH) and subarachnoid hemorrhage (SAH)
account for 15% and 5% of all strokes, respectively.
The hematoma increases intracranial pressure and is
associated with oxidative stress, inflammation, and
cell death (Mracsko & Veltkamp, 2014; Pluta et
al., 2009). However, the direct contribution of the
vasculature, blood or its components to disease patho-
physiology remains to be elucidated.
Recent studies suggest that early brain injury
following SAH is caused by constriction of pial
arterioles (Friedrich et al., 2012). Nikolaus Plesnila
(Munich, Germany) demonstrated that nitric oxide
inhalation improved vasospasm in both microvascu-
lature and large cerebral vessels following SAH in
mice (6–8 weeks old). In addition, it also reduced
cerebral edema and neuronal cell death, increased
survival and improved neurological function in the
animals (Terpolilli et al., 2015).
Oliver Kempski (Mainz, Germany) showed that
infusion of autologous blood in a rat model of
acute subdural hematoma increased lesion growth,
microglia and astrocyte activation and worsened
behavioral deficits. Intracranial pressure and cerebral
blood flow were comparable between both groups
(Jussen et al., 2016).
Marietta Zille (New York, USA) systematically
investigated cell death mechanisms in an in vitro
model of hemorrhagic stroke in primary E15 CD1
mouse cortical neurons. Similar to ischemic stroke,
hemorrhagic stroke appears to induce death via reg-
ulated necrosis, although preliminary data indicate
that cell death is not via parthanatos but rather via
necroptosis or ferroptosis, an iron-dependent form of
cell death.
Breakdown of hemoglobin further leads to iron
overload thought to mediate part of the observed
neuronal toxicity following hemorrhage. Preclinical
evidence suggests that the iron chelator deferoxamine
mesylate (DFO) protects against hemorrhagic stroke
in aged (18 months old) rats (Okauchi et al., 2009).
Magdy Selim (Boston, USA) discussed the ongo-
ing efforts to develop DFO as a treatment for ICH
patients. A phase I clinical trial established that daily
infusions of DFO after ICH are feasible and well tol-
erated without causing serious adverse events (Selim
et al., 2011). However, a subsequent phase II clini-
cal trial using high doses of DFO was stopped due
to an increased incidence of acute respiratory dis-
tress syndrome (ClinicalTrials.gov NCT01662895),
and a modified protocol (iDEF) is currently underway
(ClinicalTrials.gov NCT02175225). Magdy Selim
stressed that transitional research is difficult and
imperfect. While initial supporting proof-of-concept
animal data is important, ongoing bi-directional
94 H.-U. Demuth et al. / Proceedings from the 9th International Symposium on Neuroprotection & Neurorepair
communications between basic researchers and clini-
cians are required at all stages. He also questioned the
cost-effectiveness and reliability of phase-I, small,
dose-finding, studies and spoke about the need for
future evaluation of alternative approaches for drug
delivery to minimize systemic toxicity.
The presented studies highlight that blood is a
major contributor to cell death and outcome follow-
ing hemorrhagic stroke. Future studies will further
elucidate the underlying mechanisms and allow
for development of novel therapeutic options for
hemorrhagic stroke patients beyond the currently
existing, more mechanistically driven approaches of
hematoma evacuation, substitution of coagulation
factors and blood pressure regulation.
4. Getting closer with clinical translation
4.1. The role of large animal models of CNS
injury
Animal models are essential in understanding the
complex pathophysiology of neurological diseases,
with the selection of appropriate animal models being
fundamental to clinical success. In recent years, there
has been resurgence in the use of large animal mod-
els of CNS injury, for example stroke, traumatic brain
injury and spinal cord injury. Such models provide an
intermediate to validate interventions of outstanding
promise identified in rodent models prior to clinical
assessment, because such a rigorous step-wise vali-
dation is more likely to yield greater clinical success.
Recent developments in animal models of CNS injury
were presented in the symposium. Whilst the clinical
translation of novel therapeutic agents for stroke has
been extremely poor to date, Matthew Gounis high-
lighted that in contrast there has been great success
in the translation of medical devices for mechanical
thrombectomy. Indeed, combining in vitro (van der
Marel et al., 2016; Chueh et al., 2012, 2013) with
in vivo models (Gounis et al., 2013; Nogueira et al.,
2012; van der Bom et al., 2011) was described as a
way to provide evidence to direct device development
and implementation.
Rene´e Turner (Adelaide, Australia) described a
number of ovine CNS injury models including tran-
sient/permanent stroke (Wells et al., 2015), traumatic
brain injury and concussion. The advantages of the
sheep as a model for CNS injury were detailed. For
Fig. 2. Comparison between rodent, ovine and human brain. Although significantly smaller than the human brain, the ovine brain is also
gyrencephalic and exhibits a grey-to-white-matter ration more similar to humans as compared to the rodent brains. Sheep are therefore
considered an interesting model species for translational neuroscience.
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example, sheep have a more human-like brain struc-
ture (Fig. 2) that includes a gyrencephalic pattern,
clear anatomical discrimination between grey and
white matter (including dense white matter tracts),
strong fibrous dura mater and tentorium cerebelli, and
large size compared with the rodent brain, in addi-
tion to a remarkably similar cerebrovascular anatomy
(with the exception of the rete mirabile).
Anna Leonard (Adelaide, Australia) outlined a
porcine model of spinal cord injury and demonstrated
the advantages of this model over smaller models.
Particularly, the anatomical size of the spinal cord and
intrathecal space, in addition to the ability to perform
clinically relevant procedures, including imaging and
intrathecal pressure monitoring, improve the poten-
tial translation to the clinic (Lee et al., 2013; Jones
et al., 2012).
In summary, the number and quality of large
animal models of CNS injury has increased tremen-
dously over the past few years and may represent one
approach to overcome the translational roadblock and
improve outcome for patients with CNS injury.
4.2. Current challenges and next steps
for endovascular treatments
In 2015, mechanical thrombectomy has robustly
shown beneficial effects in large randomized clin-
ical trials, mainly by demonstrating an improved
functional outcome but also reduced lesion size and
decreased mortality (Campbell et al., 2015). Clini-
cians are recently challenged by the optimum kind
of sedation, since general anesthesia was found to
be associated with a worsened outcome (Dhakal
et al., 2015), the fastest track to recanalization
while considering intra-hospital proceedings (e.g.
characterized by the ‘door-to-recanalization’ time),
and the increasing need of capacities for post-
interventional intensive care. However, on the fringes
of the 9th ISN&N, neuroscientists and clinicians dis-
cussed about the potential impact of neuroprotective
approaches that could be applied simultaneously with
mechanical thrombectomy. Considering the lack of
positive translations from hopeful pre-clinical neu-
roprotective strategies, the newly established kind
of acute vessel re-opening via the intra-arterial
route offers a potent chance to place neuroprotec-
tive drugs in close regional association to the initial,
ischemia-affected tissue. In this direction, hopeful
data originated from Michael E. Maniskas et al.
(2016), who noted a significant decrease in lesion
volume after intra-arterial application of verapamil
subsequent to the recanalization of the middle cere-
bral artery in mice. In a more general perspective,
new concepts for interacting within the complex path-
ways of neurotoxicity were discussed in the setting
of acute vessel recanalization. Interesting data on this
topic emerged from Jose´ Castillo et al. (2016), who
reported on the difficile glutamate ratio between the
blood and the brain, which could be modified by a
group of pharmacological active substances working
as ‘glutamate grabber’, potentially impeding effects
emerging from a glutamate-related excitotoxicity.
These approaches might represent tasks for
upcoming, translational-oriented studies, which,
however, will require the close collaboration of basic
neuroscientists, neurologists and neuroradiologists.
Pre-clinical studies that started in well-established
small animal models, exhibiting excellent standard-
ization of environmental factors as well as lesion
location and size, with confirming investigations in
large animal studies might represent a hopeful way
before strategies will be tested in the clinical setting.
5. Central and peripheral immune responses
in translational neurosciences
5.1. Immunity in post-stroke neuronal damage
and repair
Infiltration of inflammatory leukocytes is an
established feature of human stroke. Currently, the
activation of the immune system is recognized as a
key mechanism in all stages of stroke pathophysiol-
ogy, including neuronal plasticity and regeneration
(Iadecola & Anrather, 2011).
Mathias Gelderblom (Hamburg, Germany)
pointed out that innate-like lymphocytes contribute
to the tissue damage via local production of IL-17,
which leads to a subsequent detrimental infiltration
of neutrophils (Gelderblom et al., 2012). All data
were obtained in models using adult mice. Kate
Lykke Lambertsen demonstrated neuroprotective
effects of microglial-derived transmembrane-TNF.
She reported that the selective blockade of soluble-
TNF is associated with beneficial effects in a mouse
model of experimental stroke (Madsen et al., 2015).
Arthur Liesz (Munich, Germany) reviewed the role
of post-stroke immunomodulation. He emphasized
that cerebral ischemia results in a multiphasic
dysbalance of the peripheral immune homeostasis.
A strong over-activation of peripheral immunity in
the acute phase is followed by a low-grade chronic
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inflammatory state in the chronic phase. Employing
multiphoton microscopy, Jens Neumann (Magde-
burg, Germany) reported data from rodent studies
indicating that microglia are recruited to injured
neurons, where they exert neuroprotective effects
(Neumann et al., 2008). Finally, Halina Offner
(Portland, USA) demonstrated the protective role
of a sub-population of B cells, called regulatory B
cells (Bregs). Data from her lab showed that IL-10+
B-cells elicited protective effects by decreasing
the proinflammatory status of the microglia, and
by inducing an anti-inflammatory M2 phenotype
in microglia in eight-week old female C57BL/6
wild-type mice (Benedek et al., 2016).
Overall, the talks highlighted recent developments
in post-stroke immunology. On one side, divergent
roles of immune cell subpopulations in inflammatory
collateral damage and neuroprotection after stroke
were addressed. On the other side, the differing roles
of brain-invading leukocytes in the chronic stages
after brain injury for neuronal regeneration and repair
mechanisms were emphasized.
5.2. The spleen as a novel target for stroke
therapies
The spleen session focused on the last 10 years
of basic and clinical research supporting a role for
the spleen in the pathophysiology of ischemic stroke.
Halina Offner initially discussed her seminal discov-
eries that the spleen contracts after stroke and releases
inflammatory cells into the circulation (Pennypacker
& Offner, 2015; Offner et al., 2006). These studies
along with others in the field have stimulated research
on the spleen, an important component of the immune
response to stroke.
Dr. Offner (Portland, USA) discussed sex differ-
ences in spleen responses that have clear implications
for the development of immunological based treat-
ments in stroke patients (Banerjee et al., 2013).
Consequently, the spleen became a potential target for
new therapies. For example, Robert Mays (Cleveland,
USA) discussed how a specific bone marrow-derived
adherent stem cell line (MultiStem) may reduce brain
injury and promote recovery through mechanisms
involving the spleen. Dr. Mays presented the results
of a double-blind, placebo-controlled clinical trial
in which acute stroke patients were randomized to
receive intravenous infusion of MultiStem or placebo
within 24 to 48 hours after symptom onset (Hess et al.,
2014). Sean Savitz (Houston, USA) then completed
the session on clinical studies confirming that the
spleen likely reduces in size in patients with acute
stroke and that spleen contraction is associated with
higher age, prior stroke, and African-American eth-
nicity. Data were also shown that serum inflammatory
cytokines are significantly increased in patients with
contracted spleens.
6. System neuroscience: New concepts
for functional regeneration
6.1. Roots and routes for stroke recovery
Stroke leads to large-scale dysfunction of neural
networks beyond the local site of ischemic brain
injury. Reorganization of affected networks can fos-
ter functional recovery, which may be furthered with
neurostimulation techniques. Consequently, assess-
ment of stroke-induced impairments of brain circuits,
post-stroke remodeling of functional and struc-
tural connections, and effects of neurorestorative
treatments could lead to significant advancement
in stroke diagnostics, prognostics and therapeutics
(Dijkhuizen et al., 2014) (Fig. 3). Latest insights in the
characteristics, impact and mutability of post-stroke
neural network alterations were presented and dis-
cussed in the session ‘Roots and routes for stroke
recovery’.
Willem M. Otte (Utrecht, The Netherlands)
explained how different network analysis methods
inform on neural network topology from structural
and functional magnetic resonance imaging (MRI)
data. His studies in animal models and patients illus-
trated the difficulties of direct comparison between
networks in control and pathological brains, which
often differ in network density. Alternative strate-
gies, such as minimum spanning tree and generative
modeling (Sinke et al., 2016), can overcome these
issues and allow more reliable characterization
of topological network modifications after brain
injury.
Adam Q. Bauer and Jin-Moo Lee (both St. Louis,
USA) reported on changes in functional connectivity
in the post-stroke mouse brain as measured with a rel-
atively new functional imaging technique, based on
optical intrinsic signals (White et al., 2011). Restora-
tion of interhemispheric functional connectivity,
which typically coincides with post-stroke sensori-
motor recovery (Bauer et al., 2014), was impeded
by optogenetic stimulation of the contralesional
somatosensory cortex subacutely after photothrom-
botic stroke in the left somatosensory cortex. In a
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Fig. 3. Changes in neural network connectivity after stroke. (A) Schematic representation of a neural network in human brain before (left),
with nodes and edges in blue, and after stroke (right), illustrating global disconnection (red dotted edges) and reorganization (green edges)
as a result of a focal stroke lesion (black area). (B) Diffusion tensor imaging-based fiber tractography maps of control (left) and 10-weeks
post-stroke rat brain (right), showing altered fiber pathway patterns in perilesional white matter chronically after stroke. Stroke was induced
by 90-min intraluminal occlusion of the right middle cerebral artery in adult male Sprague Dawley rats. High angular (120 directions) and
spatial resolution (0.2 mm isotropic voxels) diffusion-weighted MRI data were acquired post mortem on a 9.4 T animal MRI scanner (total
scan time: 26 h). MrTrix3® software (http://www.mrtrix.org/) was used for diffusion-based tractography. Courtesy of Michel Sinke and
Willem Otte.
parallel study, whisker deprivation enhanced func-
tional remapping of the forelimb representation into
the whisker barrel cortex, which was accompanied by
improved behavioral recovery. Their studies clearly
demonstrated how post-stroke cortical remapping
and functional recovery may be influenced – nega-
tively or positively – by specific modulation of brain
activity in peri- or contralesional areas.
Randolph J. Nudo (Kansas City, USA) showed
the potential of the promising concept of closed-loop
neuromodulation in a rat model. Microelectrodes
were implanted in the premotor cortex, and microde-
vices that discriminate individual action potentials,
were used to process discriminated spikes from
multiple input channels, in order to trigger electrical
stimulation of the somatosensory cortex (Guggenmos
et al., 2013). Continuing spike-triggered cortical
stimulation through this closed-loop system
effectively improved sensorimotor function after
focal injury to the primary motor cortex, emphasiz-
ing the ability of neural interface systems to restore
functional connectivity and promote recovery after
brain damage.
6.2. Neurorehabilitation, human brain plasticity
and non-invasive neuromodulation
Yun-Hee Kim (Seoul, Republic of Korea) pro-
vided an expert overview on brain stimulation for
neural network plasticity after stroke. Based on
recent findings that motor training can increase func-
tional recovery by enhancing neuroplasticity in the
cortico-spinal tract (Lazaridou et al., 2013), she crit-
ically reviewed the clinical impact on invasive and
non-invasive stimulation paradigms. For example,
high frequency repetitive transcranial magnetic
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stimulation (Chang et al., 2010) and bilateral tran-
scranial direct current stimulation (tDCS, Sunwoo
et al., 2013) can induce functional improvements in
human stroke survivors in the subacute and chronic
phase of stroke. A possible explanation was given by
Maria Ru¨ger (Cologne, Germany), who showed that
tDCS can enhance recruitment of endogenous neuro-
progenitor cells in the adult male Wistar rat (Rueger
et al., 2012), being accompanied by improved func-
tional outcome (Fig. 4).
Complex information processing and sensory
functions may also benefit from non-invasive stimu-
lation. Dorothee Saur (Leipzig, Germany) presented
recent data on language network reorganization,
including underlying dynamics and region-specific
roles for recovery. She also introduced a potential
rational for increasing language network reorgani-
zation using non-invasive brain stimulation based
on the results of functional MRI in the sense of
aneuroimaging-guided network stimulation. In addi-
tion, she presented the results of the study by
Meinzer et al. (2016), which demonstrated increas-
ing reorganization in the language network even when
stimulation was applied to an ancillary non-damaged
network, e.g. the motor network. Bernhard Sabel
(Magdeburg, Germany) is an expert in partial blind-
ness and vision restauration (Bola et al., 2014). He
presented promising data on noninvasive repetitive
transorbital alternating current stimulation, which
induced long lasting (6 months and longer) vision
improvements in patients suffering from optic neu-
ropathy in clinical trials (Gall et al., 2011, 2016).
The trial revealed a more than 20% larger visual field
size and 60% better vision in impaired visual field
sector.
Ulf Ziemann (Tu¨bingen, Germany) reviewed
current concepts for individualized non-invasive
brain stimulation for neurorehabilitation. He showed
evidence that non-invasive brain stimulation might
change activity and excitability of brain networks
and highlighted potential supporting effects in
stroke rehabilitation. On the other hand, effect
sizes using current stimulation paradigms seem
limited. Combining stimulation with supportive ther-
apies such as pharmacotherapies might help to
further increase effect sizes (Ziemann et al., 2015),
but large scale clinical trials still need to be
conducted.
Fig. 4. Transcranial direct current stimulation (tDCS) induces neurogenesis and accelerates functional recovery after stroke in the rodent
brain. (A) Neuroblasts in the subventricular zone (SVZ) were identified by their expression of doublecortin (DCX) under control conditions
(sham, left) and after multi-session tDCS of cathodal (middle) or anodal (right) polarity. (B) Following multi-session tDCS of cathodal or
anodal polarity, the area of DCX-positive neuroblasts in the SVZ ipsilateral to tDCS was wider than under control conditions in the healthy
mouse brain (sham). (C) Rats subjected to focal cerebral ischemia by middle cerebral artery occlusion displayed a wider DCX+area of
the SVZ when treated with tDCS of cathodal or anodal polarity for 10 consecutive days after stroke. (D) Motor recovery assessed by the
Catwalk test revealed that multi-session cathodal tDCS led to a faster recovery of limb strength (‘print area’) in stroke rats compared to sham
treatment. (E) Both cathodal and anodal tDCS facilitated recovery of gait, i.e., led to less limping (‘stand’), compared to control (∗p < 0.05).
Figure elements were modified from Pikhovych et al., 2016 and Braun et al., 2016 with permissions.
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7. Conclusions and outlook
The deepened understanding of pathophysiologi-
cal mechanisms behind neurovascular disorders and
a multitude of novel and well validated findings
sustain the hope that our therapeutic options arse-
nal may be both augmented and improved in the
mid-term future. On the other hand, the previous
decades of unsuccessful therapeutic research in the
field has yielded caution and exemplified the need
for interdisciplinary collaboration to reflect com-
plex clinical situations. This includes the detrimental
interaction of common comorbidities with acute and
chronic neurodegenerative disorders (Lucke-Wold
et al., 2012). Consequently, novel ideas and collab-
orative concepts to overcome or at least bypass the
still existing translational roadblock are intensively
discussed throughout the neuroscience community
(Boltze et al., 2016; Dirnagl et al., 2013) and the first
multicenter preclinical trial was already concluded
(Llovera et al., 2015). Next to its traditional topics,
the 10th ISN&N will consequently also put the spot-
light on these novel formats, systemic neuroscience
and clinical translation. It will also feature a higher
proportion of dementia-related research. The ISN&N
anniversary meeting will take place in April 2018 in
Dresden, Germany (www.neurorepair-2018.de).
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